Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Revue D'Histoire De La Pharmacie
|
July 21, 2015
[Studying at École de pharmacie de Lille with Alfred Giard in the XIXth century]
Mathieu Guerriaud
Pharmaceutical Medicine
|
December 9, 2023
"Regulatory Sandboxes" Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products
Mathieu Guerriaud
European Journal of Health Law
|
January 25, 2024
The Proposal for a Directive on Defective Products: A Game Changer for Innovative Medicinal Products
Mathieu Guerriaud, Valérie Siranyan
Frontiers in Medicine
|
November 3, 2022
RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation
Mathieu Guerriaud, Evelyne Kohli
Actualites Pharmaceutiques
|
September 29, 2021
[The pharmacist and informed consent]
Jean-Michel Mrozovski, Mathieu Guerriaud
Gene Therapy
|
March 1, 2024
Are genetically modified protozoa eligible for ATMP status? Concerning the legal categorization of an oncolytic protozoan drug candidate
Mathieu Guerriaud, Cyril Poupet, Zineb Lakhrif, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 19, 2019
Low Cross-Reactivity Between Cisplatin and Other Platinum Salts
Justine Pasteur, Laure Favier, Corinne Pernot, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 7, 2023
Why is there no biosimilar of Erbitux®?
Emmanuel Douez, Valentina D'Atri, Davy Guillarme, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Revue D'Histoire De La Pharmacie
|
July 21, 2015
[Studying at École de pharmacie de Lille with Alfred Giard in the XIXth century]
Mathieu Guerriaud
Pharmaceutical Medicine
|
December 9, 2023
"Regulatory Sandboxes" Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products
Mathieu Guerriaud
European Journal of Health Law
|
January 25, 2024
The Proposal for a Directive on Defective Products: A Game Changer for Innovative Medicinal Products
Mathieu Guerriaud, Valérie Siranyan
Frontiers in Medicine
|
November 3, 2022
RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation
Mathieu Guerriaud, Evelyne Kohli
Actualites Pharmaceutiques
|
September 29, 2021
[The pharmacist and informed consent]
Jean-Michel Mrozovski, Mathieu Guerriaud
Gene Therapy
|
March 1, 2024
Are genetically modified protozoa eligible for ATMP status? Concerning the legal categorization of an oncolytic protozoan drug candidate
Mathieu Guerriaud, Cyril Poupet, Zineb Lakhrif, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 19, 2019
Low Cross-Reactivity Between Cisplatin and Other Platinum Salts
Justine Pasteur, Laure Favier, Corinne Pernot, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 7, 2023
Why is there no biosimilar of Erbitux®?
Emmanuel Douez, Valentina D'Atri, Davy Guillarme, et al.
Page
of 1